204 related articles for article (PubMed ID: 15191689)
1. Novel therapies for pancreatic adenocarcinoma.
Pino SM; Xiong HQ; McConkey D; Abbruzzese JL
Curr Gastroenterol Rep; 2004 Apr; 6(2):119-25. PubMed ID: 15191689
[TBL] [Abstract][Full Text] [Related]
2. Novel therapies for pancreatic adenocarcinoma.
Pino SM; Xiong HQ; McConkey D; Abbruzzese JL
Curr Oncol Rep; 2004 May; 6(3):199-206. PubMed ID: 15066231
[TBL] [Abstract][Full Text] [Related]
3. Advanced pancreatic cancer: is there a role for combination therapy?
Kulke MH
Expert Rev Anticancer Ther; 2003 Oct; 3(5):729-39. PubMed ID: 14599095
[TBL] [Abstract][Full Text] [Related]
4. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Saif MW
JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?
Kleespies A; Jauch KW; Bruns CJ
Drug Resist Updat; 2006; 9(1-2):1-18. PubMed ID: 16621676
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
[TBL] [Abstract][Full Text] [Related]
8. [Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
Ryu JK
Korean J Gastroenterol; 2015 Sep; 66(3):150-3. PubMed ID: 26387697
[TBL] [Abstract][Full Text] [Related]
9. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs in pancreatic cancer.
Ducreux M; Boige V; Malka D
Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
[TBL] [Abstract][Full Text] [Related]
11. Advances in non-operative therapy in pancreatic cancer.
Brammer R; Buckels J; Bramhall S
Int J Clin Pract; 2000; 54(6):373-81. PubMed ID: 11092111
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Zafar SF; El-Rayes BF
Am J Clin Oncol; 2014 Apr; 37(2):194-200. PubMed ID: 22643564
[TBL] [Abstract][Full Text] [Related]
13. Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Zhao J; Shen H; Hu HG; Huang JJ
World J Gastroenterol; 2015 Mar; 21(11):3441-6. PubMed ID: 25805958
[TBL] [Abstract][Full Text] [Related]
14. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Kourie HR; Gharios J; Kattan J
Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
[No Abstract] [Full Text] [Related]
15. Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
Zalatnai A
Cancer Treat Rev; 2007 May; 33(3):289-98. PubMed ID: 17343986
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
17. [Salvage chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer: survival benefit in selected patients].
Lee JL; Kim YT
Korean J Gastroenterol; 2008 Jul; 52(1):59-63. PubMed ID: 19077495
[No Abstract] [Full Text] [Related]
18. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer: what the oncologist can offer for palliation.
Moore MJ
Can J Gastroenterol; 2002 Feb; 16(2):121-4. PubMed ID: 11875597
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for advanced pancreatic cancer.
El-Rayes BF; Philip PA
Expert Rev Anticancer Ther; 2002 Aug; 2(4):426-36. PubMed ID: 12647986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
